Platinum drugs in the Australian cancer chemotherapy healthcare setting: Is it worthwhile for chemists to continue to develop platinums?

Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel

“…Like all other platinum drugs, cisplatin is initially effective in killing cancer cells, but resistance eventually develops 26 - 30 . Even with side effects, cisplatin is still used in initial clinical therapies and administered to recurrent and/or metastatic cancer patients 31 - 33 . We have previously observed that treatment of murine mammary tumors with cisplatin initially suppressed tumor growth, but drug resistance occurred after prolonged drug exposure, leading to uncontrolled tumor recurrence and growth 34 .…”

Structure‐activity relations of Pd(II) and Pt(II) thiosemicarbazone complexes on different human glioblastoma cell lines

“…[3] In a recent study, it was reported that the three generally approved compounds cisplatin, carboplatin, and oxaliplatin were used in 25 % of the evaluated chemotherapeutic protocols. [4] Cisplatin was also examined in the context of glioblastoma treatment and shown to be active in vitro, but in a clinical phase III study it did not improve median survival while at the same time showing more serious toxicity than standard therapy. [5] Further studies suggested that this might be due to the activity of atypical protein kinases C (PKCι and PKCζ), which are also thought to have a role in leukaemia cell chemoresistance.…”

Bone tumor–targeted delivery of theranostic 195mPt-bisphosphonate complexes promotes killing of metastatic tumor cells

“…Platinum (Pt)-based drugs are widely used for the treatment of 24 specific types of cancer [ 3 ]. Traditional Pt drugs such as cisplatin consist of two non-leaving amine groups and two additional leaving ligands that can bind DNA to induce DNA damage [ 4 ].…”